MDT vs TMDX
MDT: Global medical device leader deploying pacemakers, defibrillators, spinal implants, surgical robotics, and diabetes management systems to alleviate pain, restore health, and extend life across 150+ countries. TMDX: TransMedics is a medical technology company providing a portable organ perfusion system designed to optimize the quality and availability of donor organs for transplant.
Side-by-side fundamentals
| Metric | MDT | TMDX | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $93.35 | $94.77 | |
| Market cap as of 2026-08-24 | $119.5B | $3.3B | |
| P/E as of 2026-08-24 | 24.25 | 20.44 | TMDX lower |
| PEG as of 2026-08-24 | 3.09 | 0.24 | TMDX lower |
| Net margin as of 2026-08-24 | +13.2% | +22.7% | TMDX higher |
| Gross margin as of 2026-08-24 | +65.8% | +58.7% | MDT higher |
| Operating margin as of 2026-08-24 | +17.8% | +12.2% | MDT higher |
| ROE as of 2026-08-24 | +9.8% | +33.0% | TMDX higher |
| ROA as of 2026-08-24 | +5.2% | +12.3% | TMDX higher |
| Debt / equity as of 2026-08-24 | 0.57 | 1.66 | MDT lower |
| Revenue growth (YoY) as of 2026-08-24 | +8.4% | +25.8% | TMDX higher |
| Revenue CAGR (3y) SEC XBRL | +5.2% | +86.4% | TMDX higher |
| Dividend yield as of 2026-08-24 | +3.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | 0 | MDT higher |
| Beta as of 2026-08-24 | 0.57 | 1.99 | |
| 1-year return as of 2026-08-21 close | +2.5% | -20.2% | MDT higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.